Who makes Prototype BMS-986165?

Prototype BMS-986165 is developed by Bristol-Myers Squibb.

What development phase is Prototype BMS-986165 in?

Prototype BMS-986165 is in Phase 1.

Last reviewed 2026-04-19 · How we verify

Prototype BMS-986165

Bristol-Myers Squibb · Phase 1 active Small molecule

At a glance

Generic name	Prototype BMS-986165
Also known as	Deucravacitinib
Sponsor	Bristol-Myers Squibb
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Evaluate the Drug Levels of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants (PHASE1)
A Study to Determine the Pharmacokinetic Profile of BMS-986165 Tablets (PHASE1)
Pharmacokinetics (Drug Levels in Blood) of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Prototype BMS-986165 CI brief — competitive landscape report
Prototype BMS-986165 updates RSS · CI watch RSS
Bristol-Myers Squibb portfolio CI